The Metformin Immunoregulatory Actions in Tumor Suppression and Normal Tissues Protection

Title:The Metformin Immunoregulatory Actions in Tumor Suppression and Normal Tissues Protection

Volume: 31 Issue: 33

Author(s): Jitendra Gupta, Abduladheem Turki Jalil*, Zahraa Hamzaa Abd Alzahraa, Zafar Aminov, Fahad Alsaikhan*, Andrés Alexis Ramírez-Coronel, Pushpamala Ramaiah and Masoud Najafi*

Affiliation:

• Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, 51001, Iraq

• College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia

• Medical Technology Research Center, Institute of Health Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran

Abstract: The immune system is the key player in a wide range of responses in normal tissues and tumors to anticancer therapy. Inflammatory and fibrotic responses in normal tissues are the main limitations of chemotherapy, radiotherapy, and also some newer anticancer drugs such as immune checkpoint inhibitors (ICIs). Immune system responses within solid tumors including anti-tumor and tumor-promoting responses can suppress or help tumor growth. Thus, modulation of immune cells and their secretions such as cytokines, growth factors and epigenetic modulators, pro-apoptosis molecules, and some other molecules can be suggested to alleviate side effects in normal tissues and drug-resistance mechanisms in the tumor. Metformin as an anti-diabetes drug has shown intriguing properties such as anti-inflammation, anti-fibrosis, and anticancer effects. Some investigations have uncovered that metformin can ameliorate radiation/chemotherapy toxicity in normal cells and tissues through the modulation of several targets in cells and tissues. These effects of metformin may ameliorate severe inflammatory responses and fibrosis after exposure to ionizing radiation or following treatment with highly toxic chemotherapy drugs. Metformin can suppress the activity of immunosuppressive cells in the tumor through the phosphorylation of AMP-activated protein kinase (AMPK). In addition, metformin may stimulate antigen presentation and maturation of anticancer immune cells, which lead to the induction of anticancer immunity in the tumor. This review aims to explain the detailed mechanisms of normal tissue sparing and tumor suppression during cancer therapy using adjuvant metformin with an emphasis on immune system responses.

Cite this article as:

Gupta Jitendra, Jalil Turki Abduladheem*, Abd Alzahraa Hamzaa Zahraa, Aminov Zafar, Alsaikhan Fahad*, Ramírez-Coronel Alexis Andrés, Ramaiah Pushpamala and Najafi Masoud*, The Metformin Immunoregulatory Actions in Tumor Suppression and Normal Tissues Protection, Current Medicinal Chemistry 2024; 31 (33) . https://dx.doi.org/10.2174/0929867331666230703143907